Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Feigh

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
American Journal of Physiology. Gastrointestinal and Liver Physiology|October 15, 2024
Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosisMalte Hasle Nielsen, Jacob Nøhr-Meldgaard, Mathias Bonde Møllerhøj, et al.
Ebiomedicine|January 17, 2026
Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug developmentNina Sonne, Micaela Roque, Line Fisker Zachariassen, et al.
Physiological Reports|October 11, 2024
Reproducible lung protective effects of a TGFβR1/ALK5 inhibitor in a bleomycin-induced and spirometry-confirmed model of IPF in male miceAsbjørn Graver Petersen, Stefanie H Korntner, Jamal Bousamaki, et al.
Hepatology Communications|July 7, 2020
Activation of Adenosine Monophosphate-Activated Protein Kinase Reduces the Onset of Diet-Induced Hepatocellular Carcinoma in MiceDieter Schmoll, Nicole Ziegler, Benoit Viollet, et al.
World Journal of Gastroenterology|September 24, 2019
Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat sourceMichelle L Boland, Denise Oró, Kirstine S Tølbøl, et al.
British Journal of Pharmacology|June 9, 2024
Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitisGu-Choul Shin, Hyeong Min Lee, Nayeon Kim, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|April 13, 2026
Therapeutic Efficacy, Biomarker Signatures and Translatability of Semaglutide in the Liver Biopsy-Confirmed GAN DIO-MASH Mouse ModelJens Bjelke Kristensen, Jacob Nøhr-Meldgaard, Susanne E Pors, et al.
Nature Metabolism|June 2, 2020
Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesisMichelle L Boland, Rhianna C Laker, Karly Mather, et al.
Hepatology Communications|November 25, 2024
Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767Prakash Ramachandran, Madara Brice, Elena F Sutherland, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 26, 2020
Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivativeGeurt Stokman, Anita M van den Hoek, Ditte Denker Thorbekk, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
American Journal of Physiology. Gastrointestinal and Liver Physiology|October 15, 2024
Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosisMalte Hasle Nielsen, Jacob Nøhr-Meldgaard, Mathias Bonde Møllerhøj, et al.
Ebiomedicine|January 17, 2026
Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug developmentNina Sonne, Micaela Roque, Line Fisker Zachariassen, et al.
Physiological Reports|October 11, 2024
Reproducible lung protective effects of a TGFβR1/ALK5 inhibitor in a bleomycin-induced and spirometry-confirmed model of IPF in male miceAsbjørn Graver Petersen, Stefanie H Korntner, Jamal Bousamaki, et al.
Hepatology Communications|July 7, 2020
Activation of Adenosine Monophosphate-Activated Protein Kinase Reduces the Onset of Diet-Induced Hepatocellular Carcinoma in MiceDieter Schmoll, Nicole Ziegler, Benoit Viollet, et al.
World Journal of Gastroenterology|September 24, 2019
Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat sourceMichelle L Boland, Denise Oró, Kirstine S Tølbøl, et al.
British Journal of Pharmacology|June 9, 2024
Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitisGu-Choul Shin, Hyeong Min Lee, Nayeon Kim, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|April 13, 2026
Therapeutic Efficacy, Biomarker Signatures and Translatability of Semaglutide in the Liver Biopsy-Confirmed GAN DIO-MASH Mouse ModelJens Bjelke Kristensen, Jacob Nøhr-Meldgaard, Susanne E Pors, et al.
Nature Metabolism|June 2, 2020
Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesisMichelle L Boland, Rhianna C Laker, Karly Mather, et al.
Hepatology Communications|November 25, 2024
Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767Prakash Ramachandran, Madara Brice, Elena F Sutherland, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 26, 2020
Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivativeGeurt Stokman, Anita M van den Hoek, Ditte Denker Thorbekk, et al.
Pageof 5